What is the recommended management and treatment for chronic hepatitis B infection?

Management and Treatment of Chronic Hepatitis B Infection

For chronic hepatitis B, first-line treatment should be entecavir, tenofovir disoproxil fumarate (TDF), or tenofovir alafenamide (TAF) due to their high potency and high barrier to resistance, with treatment decisions based on HBeAg status, HBV DNA levels, ALT elevation, and presence of cirrhosis. 1

Treatment Indications

HBeAg-Positive Chronic Hepatitis B

• Treat immediately if HBV DNA >20,000 IU/mL AND ALT >2× upper limit of normal (ULN), or if liver biopsy shows significant inflammation/fibrosis (≥moderate necroinflammation or ≥periportal fibrosis) 1
• Treat without delay if signs of liver failure are present (jaundice, prolonged PT, hepatic encephalopathy, ascites) 1
• For HBV DNA >20,000 IU/mL with ALT 1-2× ULN: observe for 3-6 months or perform liver biopsy; treat if ALT rises further or biopsy shows significant disease 1
• Treatment can be delayed 3-6 months if spontaneous HBeAg seroconversion is anticipated, except in patients with apparent liver failure 1

HBeAg-Negative Chronic Hepatitis B

• Treat immediately if HBV DNA >2,000 IU/mL AND ALT >2× ULN, or if biopsy shows significant inflammation/fibrosis 1
• For HBV DNA >2,000 IU/mL with ALT <2× ULN: observe or perform liver biopsy; treat if ALT subsequently rises or biopsy shows significant disease 1
• Monitor with ALT every 3 months and HBV DNA every 6-12 months for at least 3 years if not treating 1

Compensated Cirrhosis

• Treat all patients with compensated cirrhosis and detectable HBV DNA, regardless of ALT levels 1
• ALT should not be used as treatment criteria in cirrhotic patients since they already have significant fibrosis and frequently have near-normal ALT 1
• Non-invasive methods (such as FibroScan) are extremely useful to confirm or rule out cirrhosis in patients starting treatment without biopsy 1

Decompensated Cirrhosis

• Urgent antiviral treatment with nucleos(t)ide analogues is required for all patients with decompensated cirrhosis and detectable HBV DNA 1
• Consider liver transplantation simultaneously, as antiviral therapy may not rescue patients with very advanced disease 1
• Never use interferon in patients with decompensated cirrhosis due to risk of hepatic decompensation 1

First-Line Treatment Options

Preferred Nucleos(t)ide Analogues

Monotherapy with entecavir, tenofovir (TDF or TAF), or peginterferon-α is preferred as first-line treatment 1

Entecavir

• Dose: 0.5 mg daily for treatment-naïve patients 1
• Resistance rate: only 1.2% after 5 years in treatment-naïve patients 1
• Achieves HBV DNA <60-80 IU/mL in 90% of HBeAg-negative patients at 12 months 1

Tenofovir Disoproxil Fumarate (TDF)

• Dose: 245 mg daily 1
• No resistance reported after 1.5 years in treatment-naïve patients 1
• Achieves HBV DNA <60-80 IU/mL in 93% of HBeAg-negative patients at 12 months 1
• Monitor renal function and bone mineral density during long-term treatment 1

Tenofovir Alafenamide (TAF)

• Preferred over TDF in patients with renal dysfunction or metabolic bone disease risk factors 1
• Superior safety profile regarding renal and bone effects compared to TDF 1
• Achieves high rates of viral suppression (96.7% in HBeAg-positive, 82.1% in HBeAg-negative patients) 1

Peginterferon Alfa-2a

• Dose: 180 μg subcutaneously once weekly for 48 weeks 1
• Advantage: finite treatment duration and no resistance 1
• Disadvantages: requires injection, many side effects, expensive 1
• Can be used with caution in compensated cirrhotic patients with preserved liver function, but requires careful monitoring 1

Drugs NOT Recommended as First-Line

Lamivudine and adefovir are not recommended as first-line therapy due to inferior efficacy and high resistance rates 1

• Lamivudine: resistance develops in up to 70% during first 5 years 1
• Adefovir: inferior antiviral efficacy compared to tenofovir 1
• These may be used only in special circumstances: short-term prophylaxis during chemotherapy, pregnancy, HIV-HBV coinfection, or combination therapy in hepatic decompensation 1

Monitoring During Treatment

Response Assessment

• Measure HBV DNA every 3-6 months after achieving complete virologic response at week 24 1
• For partial virologic response at week 24 with low genetic barrier drugs (lamivudine, telbivudine, adefovir): switch to high genetic barrier drug (entecavir or tenofovir) 1
• For partial response with high genetic barrier drugs: continue treatment with regular monitoring for viral breakthrough 1

Viral Breakthrough Management

• Implement rescue therapy according to genotypic resistance analysis results 1
• Test for genotypic resistance mutations in patients with primary treatment failure and good compliance 1
• Switch to high genetic barrier drug if resistance mutations identified while on low barrier drug 1

Treatment Duration

HBeAg-Positive Patients

• Minimum 1 year of treatment 1
• Continue for 3-6 months after confirmed HBeAg seroconversion (on two occasions at least 2 months apart) to reduce relapse 1
• Long-term treatment necessary in most patients as HBeAg seroconversion rates remain modest 1

HBeAg-Negative Patients

• Treatment duration longer than 1 year required 1
• Relapse rates 80-90% if treatment stopped at 1-2 years 1
• Indefinite treatment recommended for most patients 1

Cirrhotic Patients

• Indefinite nucleos(t)ide analogue treatment recommended in all patients with cirrhosis 1
• Withdrawal almost always accompanied by viral relapse 1

Special Populations

Pregnancy

• Prophylactic antiviral therapy in last trimester for women with high viremia to prevent vertical transmission 1, 2
• Consider switching to pregnancy category B agents (telbivudine, tenofovir) if already on treatment 1
• Lamivudine and tenofovir have known safety experience during pregnancy 1

Immunosuppression/Chemotherapy

• Prophylactic antiviral therapy required to prevent HBV reactivation 1, 2
• HBsAg-positive patients undergoing anticancer treatment should receive prophylactic nucleos(t)ide analogues regardless of detectable HBV DNA 1
• Monitor for HBV reactivation even in HBsAg-negative/anti-HBc-positive patients receiving intensive treatment 1

Liver Transplantation

• Prophylactic treatment mandatory to prevent HBV recurrence 1
• Combination of hepatitis B immunoglobulin (HBIG) and nucleos(t)ide analogues traditionally used 1
• Selected low-risk patients may discontinue HBIG 6-12 months post-transplant per recent guidelines 3

Renal Dysfunction

• Adjust nucleos(t)ide analogue doses according to creatinine clearance 1
• Tenofovir AF preferred over TDF in patients with chronic kidney disease 1
• Tenofovir AF and TDF not recommended with creatinine clearance <15 and <10 mL/min respectively without renal replacement 1

Acute Hepatitis B

• Antiviral therapy generally not recommended as >95% recover spontaneously 1
• Treat immediately in cases of persistent serious hepatitis or acute liver failure 1

Treatment Goals

Primary Goals

• Suppress HBV replication to undetectable levels 1
• Normalize ALT 1
• Prevent progression to cirrhosis, hepatocellular carcinoma, and liver-related mortality 1

Optimal Endpoint

• HBsAg loss represents the optimal endpoint 1
• However, HBsAg loss rates remain low with current therapies: 3.4-4.9% after 10 years of tenofovir 1
• HBeAg seroconversion in HBeAg-positive patients is an important intermediate endpoint 1

Common Pitfalls to Avoid

• Do not use ALT as sole criterion for treatment in cirrhotic patients - they often have normal ALT despite significant disease 1
• Do not use interferon in decompensated cirrhosis - risk of hepatic failure 1
• Do not start lamivudine or adefovir as first-line unless specific circumstances warrant it 1
• Do not stop monitoring after HBV DNA suppression - HCC risk persists despite viral control 1
• Do not discontinue treatment prematurely in HBeAg-negative patients - high relapse rates 1